Søgning på udtrykket 'hiv' giver 157 resultater
Dokumenter [13]
Sider [7]
Kalender [88]
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Dokumenter [13]
Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).
Version: 3. Endelig guideline: 01.09.2020. Guideline skal revideres senest: 01.09.2023
Arbejdsgruppens medlemmer: Peer Brehm Christensen, Christian Erikstrup, Jan Gerstoft, Terese Katzenstein, Alex Laursen, Suzanne Lunding, Birgitte Mørn og Nina Weis.
Arbejdsgruppen bestod af: Jan Gerstoft, Ann-Brit Eg Hansen, Gitte Kronborg, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen, Niels Obel og Alex Laursen
Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.
medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering.
Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi.
Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.
Senest revideret september 2021 . Arbejdsgruppen bestod af: Jan Gerstoft, Gitte Kronborg , Ann Brit Eg Hansen, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen , Niels Obel og Alex Laursen
Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Arrangeret af Yngre Infektionsmedicinere
Correspondence regarding "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy"
Henvendelse til Danske regioner
Sider [7]
Formål:
At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme.
Tid og sted:
Hvidovre Hospital. Lokale 10 i undervisningsbygningen.
Delkursusledere:
Ann-Brit Eg Hansen og Ole Kirk.
Program:
Mandag 3. oktober:
10:00-10:15 Velkomst og introduktion (Ann-
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
epatitis:
Carsten Shade Larsen og Nina Weis.
Hepatitis A (2013),
Antiretroviral terapi:
Henrik Nielsen, Jan Gerstoft, Jens Lundgren, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen
Antiviral behandling af hiv smittede personer (2021),
Fertilitetsbehandling ved HIV og hepatitis B og C (2018),
HIV behandling af gravide (2021),
HIV post exposure profylakse (2020),
Pre-exposure profylakse mod HIV (2021),
Borrelia:
Anne-Mette Lebech (tovho
terologiske infektioner og kronisk hepatitis:
Dato for næste kursus
2026:
Sted
Odense Universitetshospital
Delkursusledelse
Lone Mygind, Micha Jepsen og Belinda Mössner
Tidligere kurser
4. og 5. december 2023
3. og 4. december 2020
HIV-infektion:
Næste kursus
Efterår 2025 (2 dage):
Sted
Afventer
Delkursusledelse
Ole Schmeltz Søgaard og Lene Ryom Nielsen
Program
Afventer
Tidligere kurser
12. og 13. oktober 2022
7. og 8. oktober 2019
3. og 4. oktober 2016
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV. De udfordringer som den vestlige verden, trods udbredt og gratis behandlingstilbud, har med at få styr på smittespredning blandt fx mænd-der-har-sex-med-mænd viser, at det - der intuitivt synes ligefor - ikke nødvendigvis virker når det kommer t
Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring.
Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler. Det har været debatteret om forskelle i antiretrovirale lægemidlers penetrans over blod/hjerne barrieren har betydning for HAND og for AIDS-definerende opportunistisk infektion i hjernen.
Der er ingen tvivl om at koncentr
Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig).
Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem.
Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud
Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den
Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling. Omkostning ifm nyttevirkning er central i at forbedre be
dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III). Dette faktum er universelt og set for praktisk tage
Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.
Professor Lars Østergaard kommenterer: Indimellem kommer der studier, som er så overbevisende, at det sætter en ny behandlingsstandard.
Det kan f.eks. være Lundgrens studie af, hvornår man kan holde op med at give pneumocyste-profylakse til HIV-smittede eller de Gans studiet, der ændrede fik indført dexamethason i retningslinjerne for purulent meningitis.
Her er formentlig et nyt studie, der kommer til at få indflydelse på standardbehandlingen af patienter med svær pneumoni.
Læs en gang - og d
Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ). Forfatterne beretter at 20 TBI-positive personer skulle behandles for at forhindre ét tilfælde af TB, og at antallet, der
Kalender [88]
27. oktober 2024, Glasgow, Skotland
27. september, Stockholm, Sverige
24. august, Emil Aarestrup Auditorium, Odense Universitetshospital
23. juli, Brisbane, Australien og virtuelt
1. juni, Mærsk Tårnet, Panum Instituttet, København
10. maj, Avignon, Frankrig
27. januar, Karen Brahe auditoriet, Odense Adelige Jomfrukloster (og online)
14. december 2022, Statens Institut for Folkesundhed og online
23. oktober 2022, Glasgow, Skotland
20. oktober 2022, Washington DC, USA
12. oktober 2022, Hvidovre Hospital
28. september 2022, Stockholm, Sverige
22. september 2022, Barcelona, Spanien
10. juni 2022, Panum, København
17. maj 2022, Niels K. Jerne auditoriet, Panum Instituttet, København
10. maj 2022, Avignon, Frankrig
6. december 2021, Rigshospitalet
26. november 2021, Panum, København
30. september 2021, Barcelona, Spanien
18. juli 2021, Berlin, Tyskland
28. oktober 2020, Paris, Frankrig
25. oktober 2020, Glasgow, Skotland
28. august 2020, Online og Henrik Dam auditoriet, Maersk Tårnet
10. marts 2020, KolleKolle, Værløse
7. oktober 2019, København
11. september 2019, DGI-byen, København
21. juli 2019, Mexico City, Mexico
22. maj 2019, Rom, Italien
13. maj 2019, København, Odense, Aarhus
6. marts 2019, KolleKolle, Værløse
2. november 2018, Mærsk Tower, København
28. oktober 2018, Glasgow, Skotland
30. maj 2018, Rom, Italien
16. maj 2018, Marseille, Frankrig
4. maj 2018, Hindsgavl, Middelfart
28. februar 2018, Nielsine Nielsen Auditorium, Mærsk Tårnet, København
23. februar 2018, Syddansk Universitet, Odense
1. februar 2018, Nielsine Nielsen auditoriet, Mærsk Tårnet, København
6. oktober 2017, Holst Auditoriet, Mærsk tårnet, København
8. juni 2017, Hvidovre Hospital
4. maj 2017, Odense Universitetshospital
18. april 2017, Auditorium 93, Rigshospitalet
23. oktober 2016, Glasgow, Skotland
3. oktober 2016, Hvidovre Hospital
18. september 2016, Brisbane, Australien
25. maj 2016, Rom, Italien
29. april 2016, Hindsgavl, Middelfart
7. januar 2016, Medicinsk Museion, København
18. december 2015, Emil Aarestrup auditorium, Odense Universitetshospital
24. november 2015, Hvidovre Universitetshospital
8. september 2015, Panum Instituttet, København
18. juni 2015, Rigshospitalet, Teilum B
12. juni 2015, Medicinsk Museion, København
3. juni 2015, Barcelona, Spanien
24. april 2015, Auditorium 93, Rigshospitalet
17. april 2015, Foredragssalen, Statens Serum Institut
19. marts 2015, Auditorium 1, Rigshospitalet
2. november 2014, Glasgow, Skotland
5. oktober 2014, Barcelona, Spanien
5. juli 2014, Sigtuna, Sverige
18. juni 2014, Store Auditorium, Winsløwparken 15, st., 5000 Odense C
22. april 2014, Auditorium 5, Hvidovre Hospital
26. marts 2014, Barcelona, Spanien
20. februar 2014, Rigshospitalet
25. oktober 2013, Hannover auditoriet, Panum Instituttet, København
30. juni 2013, Kuala Lumpur, Malaysia
10. juni 2013, Centre for Medical Parasitology, København
3. maj 2013, Hindsgavl, Fyn
20. marts 2013, Rom, Italien
3. marts 2013, Atlanta, Georgia, USA
14. januar 2013, Auditorium 2, Rigshospitalet
10. november 2012, Auditorium 2, Rigshospitalet
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
23. oktober 2012, Rigshospitalet
2. oktober 2013, San Francisco, USA
27. september 2012, Auditorium 1, Bartholinbygningen, bygning 1241, lokale 135, Aarhus Universitet
29. februar 2012, SSI, København
9. december 2011, Rigshospitalet, københavn
7. november 2011, Auditorium 93, Rigshospitalet
13. maj 2011, Panum instituttet, København
29. april 2011, Auditorium B, Skejby
12. april 2011, Auditorium 100, Campusvej 55, 5230 Odense M, Syddansk Universitet
30. november 2007, Panum Instituttet, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
BMJ Open
9.12.2023
. Objectives. HIV-induced chronic inflammation, immune activation and combination antiretroviral therapy (cART) are linked with adverse metabolic changes known to cause cardiovascular adversities. This study evaluates the prevalence of lipodystrophy, and metabolic syndrome (MetS), and analyses risk factors in HIV-infected Ethiopians taking cART. . Methods. A multicentre cross-sectional study was conducted at tertiary-level hospitals. Eligible participants attending the HIV clinics were enrolled. Sociodemog
BMC Infectious Diseases
9.12.2023
. Abstract. . Background. HIV has become a manageable chronic condition due to the success and scale-up of antiretroviral therapy (ART). Globally, South Africa has the highest number of people living with HIV (PLHIV) and research evidence indicates that countries with the highest burden of PLHIV have a substantial burden of obesity, hypertension (HPT) and type 2 diabetes (T2D). We sought to summarize the burden of these thre
Journal of Medical Virology
9.12.2023
Journal of Medical Virology, Volume 95, Issue 12, December 2023.
AIDS
9.12.2023
Objective: . Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases. PETRAM (NCT#:03405012) investigated whether BMD and bone turnover changes correlate. Design: . Open-label, randomized controlled trial. Setting: . Single-site, outpatient, secondary care. Participants: . Nonosteoporotic, virologically suppressed, cis-male PWH taking TDF/emtricitabine (FTC)/rilpivirine (RPV) fo
AIDS
9.12.2023
Objective: . Frailty measures vary widely and the optimal measure for predicting HIV-associated neurocognitive disorders (HAND) is unclear. Design: . A study was conducted to examine the clinical utility of three widely used frailty measures in identifying HIV-associated neurocognitive disorders. Methods: . The study involved 284 people with HIV (PWH) at least 50 years enrolled at UC San Diego's HIV Neurobehavioral Research Program. Frailty measurements included the Fried Phenotype, the Rockwood Frailt
AIDS
9.12.2023
Objective: . This study aimed to estimate the strength of the association between anticholinergic/sedative burden and concurrent physical frailty in people aging with HIV. Design: . This cross-sectional analysis examined baseline data from 824 adults with a mean age of 53 enrolled in the Positive Brain Health Now study. Methods: . Anticholinergic medications were identified using four methods: Anticholinergic Cognitive Burden (ACB) scale, Anticholinergic Risk Scale (ARS), Anticholinergic Drug Scale (ADS)
AIDS
9.12.2023
Objective: . The primary objective of the study was to assess the immunogenicity of an HIV-1 Gag conserved element DNA vaccine (p24CE DNA) in people with HIV (PWH) receiving suppressive antiretroviral therapy (ART). Design: . AIDS Clinical Trials Group A5369 was a phase I/IIa, randomized, double-blind, placebo-controlled study of PWH receiving ART with plasma HIV-1 RNA less than 50 copies/ml, current CD4+ T-cell counts greater than 500 cells/μl, and nadir CD4+ T-cell counts greater than 350 cells/
BMC Infectious Diseases
8.12.2023
. Abstract. . Background. HIV has become a manageable chronic condition due to the success and scale-up of antiretroviral therapy (ART). Globally, South Africa has the highest number of people living with HIV (PLHIV) and research evidence indicates that countries with the highest burden of PLHIV have a substantial burden of obesity, hypertension (HPT) and type 2 diabetes (T2D). We sought to summarize the burden of these thre
PLoS One Infectious Diseases
8.12.2023
by Nambusi Kyegombe, Gbolahan Ajibola, Maureen Sakoi-Mosetlhi, Tsholofelo Rebatenne, Motswedi Anderson, Simani Gaseitsiwe, Joseph Makhema, Una Ngwenya, Sikhulile Moyo, Odile Sauzet, Lucy Mupfumi .
Journal of Acquired Immune Deficiency Syndromes
8.12.2023
Background: . Given intersecting social and structural factors, female sex workers (FSW) exhibit elevated risk of HIV and substance use. However, there is limited study of how distinct substance use typologies influence HIV treatment outcomes among FSW. Setting: . A cross-sectional survey with objective viral load assessments of 1,391 FSW enrolled into a treatment optimization-focused trial in Durban, South Africa (2018-2020). Methods: . We used latent class analysis to uncover discrete patterns in past-
Journal of Acquired Immune Deficiency Syndromes
8.12.2023
Background: . Seizures are relatively common among children with HIV in low-and middle-income countries, and are associated with significant morbidity and mortality. Early treatment with antiretroviral therapy may reduce this risk by decreasing rates of central nervous system infections and HIV encephalopathy. Methods: . We conducted a prospective, unmatched case-control study. We enrolled children with new-onset seizure from University Teaching Hospital in Lusaka, Zambia as well as two regional hospitals
Journal of Acquired Immune Deficiency Syndromes
8.12.2023
Background: . Oral PrEP and male partner HIV self-testing (HIVST) is being scaled up within antenatal clinics (ANC). Few data are available on how co-distribution influences acceptance of both interventions. Methods: . We utilized data from the PrIMA (NCT03070600) trial in Kenya. Women included in this analysis were determined to be at high risk of HIV and offered oral PrEP and partner HIVST. Characteristics were compared between women who chose: 1) PrEP and HIVST, 2) HIVST-alone, 3) PrEP-alone, or 4) dec
Journal of Acquired Immune Deficiency Syndromes
8.12.2023
Background . Background . Given the disproportionate rates of incarceration and lower life expectancy (LE) among Black sexual minority men (BSMM) and Black transgender women (BTW) with HIV, we modeled the impact of decarceration and screening for psychiatric conditions and substance use on LE of US BSMM/BTW with HIV. Methods . We augmented a microsimulation model previously validated to predict LE and leading causes of death in the US with estimates from the HPTN 061 cohort and the Veteran’s Aging Cohort
Journal of Acquired Immune Deficiency Syndromes
8.12.2023
No abstract available
American Journal of Tropical Medicine and Hygiene
7.12.2023
. . Journal Name: The American Journal of Tropical Medicine and Hygiene Volume: 109 Issue: 6 Pages: 1266-1269. .
Journal of Medical Virology
6.12.2023
Journal of Medical Virology, Volume 95, Issue 12, December 2023.
PLoS One Infectious Diseases
5.12.2023
by Soeurette Policar, Alana Sharp, Joanne Isidor Hyppolite, Gérald Marie Alfred, Eva Steide, Leïnadine Lucien, Naiké Ledan, Matthew Kavanagh . Background Failure to retain people living with HIV (PLHIV) in care remains a significant barrier to achieving epidemic control in Haiti, with as many as 30% lost from care within one year of starting treatment. Community-led monitoring (CLM) is an emerging approach of improving healthcare and accountability to service users, through a cycle of monitoring and adv
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Medscape Infectious Diseases
1.12.2023
At least 450 patients at Mass General Brigham, Salem Hospital, near Boston are at risk of HIV and hepatitis infection, according to a lawsuit claiming negligent intravenous medication administration. . Medscape Medical News
Medscape Infectious Diseases
1.12.2023
Europe's advances in HIV prevention strategies, including PrEP and long-acting retrovirals, bring hope amidst persistent access challenges and disparities. . Medscape Medical News
Eurosurveillance latest updates
1.12.2023
. Background. The global distribution of HIV-1 subtypes is evolving, which is reflected in the Swedish HIV cohort. The subtype HIV-1A6, which may be prone to developing resistance to cabotegravir, is the most common subtype in Ukraine. . . Aim. We aimed to examine trends in HIV-1 subtype distribution in Sweden, with a special focus on HIV-1A6, and to describe the virology, demography and treatment of Ukrainian people living with HIV (PLWH) who migrated to Sweden in 2022. . . Methods. Data about PLWH in
Eurosurveillance latest updates
1.12.2023
Following Russia’s invasion in 2022, over 4.1 million Ukrainians sought refuge in the EU/EEA. We assessed how this impacted HIV case reporting by EU/EEA countries. Ukrainian refugees constituted 10.2% (n = 2,338) of all 2022 HIV diagnoses, a 10-fold increase from 2021. Of these, 9.3% (n = 217) were new diagnoses, 58.5% (n = 1,368) were previously identified; 32.2% had unknown status. Displacement of Ukrainians has partly contributed to increasing HIV diagnoses in EU/EEA countries in 2022, high
Morbidity and Mortality Weekly Report (MMWR)
1.12.2023
This report describes higher proportions of deaths among children younger than 5 with HIV receiving antiretroviral treatment (ART) compared with older children and adults with HIV receiving ART.
Medscape Infectious Diseases
6.11.2023
HIV can take an emotional toll on patients whether it was diagnosed days ago or decades before, but the issues patients must contend with have changed over time. . Medscape Medical News
Medscape Infectious Diseases
31.10.2023
The monthly to bimonthly injectable regimens help overcome challenges that some patients face with daily pills. . Medscape Medical News
Medscape Infectious Diseases
27.10.2023
Preexposure prophylaxis is highly effective in preventing HIV and yet uptake can be low among women, report researchers who say mobile technologies can help. . Medscape Medical News
Eurosurveillance latest updates
6.10.2023
The infrastructure in cities provides unique opportunities to eliminate HIV. Since 2014, the HIV Transmission Elimination AMsterdam Initiative, a consortium involved in HIV prevention and care, has employed an integrated approach to curb HIV incidence in Amsterdam. This effort contributed to the 95% decline in estimated newly acquired infections and the 79% decline in observed new HIV diagnoses in Amsterdam from 2010 to 2022. In 2022, Amsterdam reached and exceeded the 95–95–95 UNAIDS treatment cascade
Statens Serum Institut
4.10.2023
Kun 38 mænd, der har sex med mænd (MSM), der er enten født eller smittet i Danmark, blev anmeldt som hiv-positive i 2022. Det er samme tal som året før, og forebyggelsesindsatsen vurderes at være lykkedes.
Medscape Infectious Diseases
20.09.2023
Primary care clinicians can provide optimal preventive care for patients at risk of contracting HIV. . Medscape Medical News
Medscape Infectious Diseases
24.08.2023
Two new antiretrovirals have been approved by the US Food and Drug Administration since the US Preventive Services Task Force's last report, which now includes new options. . Medscape Medical News
Medscape Infectious Diseases
25.07.2023
People living with HIV who are diagnosed and treated early, and take their medication as prescribed, can expect to have the same health and life expectancy as their HIV-negative counterparts. . WebMD Health News
Medscape Infectious Diseases
25.07.2023
Final data from the REPRIEVE trial show pitavastatin therapy is associated with a significantly lower risk of cardiovascular events than placebo as evidence grows for statins in primary prevention. . Medscape Medical News
Medscape Infectious Diseases
22.07.2023
Is it time to add the antibiotic doxycycline post exposure for more STIs? Doxy-PEP use is a clinical controversy that will be debated at the upcoming International AIDS Society Conference. . Medscape Medical News
Medscape Infectious Diseases
28.06.2023
Researchers are now examining the connection between HIV and menopause – and the virus's impact on a woman's health can be significant. . WebMD Health News
Morbidity and Mortality Weekly Report (MMWR)
16.06.2023
This report describes an increase in meningococcal disease cases among people with HIV during 2022 compared to previous years.
Eurosurveillance latest updates
9.06.2023
Several countries in the European Union (EU) and European Economic Area (EEA) established and/or scaled up HIV pre-exposure prophylaxis (PrEP) programmes between 2016 and 2023. Data on PrEP programmes’ performance and effectiveness in reaching those most in need will be needed to assess regional progress in the roll-out of PrEP. However, there is a lack of commonly defined indicators for routine monitoring to allow for minimum comparability. We propose a harmonised PrEP monitoring approach for the EU/EEA,
ProMED
27.05.2023
maniasis -- BrazilIntroduction: Human visceral leishmaniasis (VL) is a zoonosis of great importance to public health due to its epidemiological diversity, with emphasis on the possibility of aggravation by coinfection with the human immunodeficiency virus (HIV).Objective: The aim was to study the epidemiological characteristics of VL cases associated with HIV coinfection in Pará. Methods. Reported cases of VL from January 2006 to December 2016 were investigated. A descriptive epidemiological method related
Medscape Infectious Diseases
19.04.2023
A test for HIV, hepatitis B, and hepatitis C that uses a single dried blood spot could increase testing for these viruses in high-risk and challenging settings, new data show. . Medscape Medical News